Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises on sale of Hans Andersson Recycling to Veolia
Mandate

Vinge advises on sale of Hans Andersson Recycling to Veolia

September 01, 2017

Vinge has advised the seller in connection with the sale of all shares in Hans Recycling Group AB to Veolia Nordic AB.


Hans Andersson Recycling Group AB conducts, via approximately 15 wholly- and part owned subsidiaries, recycling operations and waste transports primarily in Sweden but also in Finland and Germany. The group has a turnover of approximately SEK 1.5 billion and employs approximately 400 persons. The competition authorities in Sweden and Germany have approved the merger.

Vinge’s team has primarily consisted of responsible partner Anders Strid, Frida Bäckegren (M&A), Mercedes Anderås (real estate and commercial leases), Johan Cederblad (environmental law), Joel Zetterström (IT), Rebecka Maltenius (commercial leases) and corporate assistant Camilla Andersson.
 

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

 Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

 Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024